Table 2.

Clinical information for infants treated with octreotide for hyperinsulinism (N = 103)

Variable	Median	Range	No. of patients
Gestational age	38 weeks	28–40 weeks	84
Birth weight	3.7 kg	1.0–5.6 kg	50
Age at study entry	15.2 weeks	0.9–313.2 weeks	103
Weight at study entry	6.4 kg	2.3–31.4 kg	103
Hospital length of stay	24.5 days	1–90 days	102
Octreotide daily dose	8.96 mcg/kg	1.33–96 mcg/kg	100
Octreotide duration	8 days	1–84 days	103
Gestational age breakdown
28 to <31 weeks*			1
31 to <34 weeks			5
34 to <37 weeks			19
37 to <40 weeks			55
≥40 weeks			4
Not recorded			19

^*28-week gestational age infant was not administered octreotide until 93 days of age.